Material and Methods: 12 patients for prostate cancer (P), and 12 for head and neck (HN) cancer, were enrolled in the study. All the treatments were delivered using the Helical Tomotherapy Hi-ART system (Accuray, Inc., Sunnyvale, CA). Pre-treatment QA measurements were performed by using the diode array ArcCHECKTM and perturbed DVHs were obtained with the 3DVH software (both by Sun Nuclear Corporation, Melbourne, FL). Measured and calculated dose distributions were compared using the global and local GI method with 2%/2 mm, and 3%/3 mm criteria. Low-dose thresholds (TH) of 10% and 30% were applied and analyzed. Percentage dose differences between DVHs, obtained by TPS and by 3DVH were calculated. A %GP equal to 95% and a mean absolute DVH 3% dose error were used as thresholds to calculate sensitivity and specificity. In order to quantify the sensitivity and specificity of GI method, we calculated the number of false negative (high Tomotherapy QA passing rates indicate large errors in anatomy dose metrics), true positive (low Tomotherapy QA passing rates do imply large errors in anatomy dose metrics), true negative (high Tomotherapy QA passing rates did imply small errors in anatomy dose metrics) and false positive (low Tomotherapy QA passing rates did imply small errors in anatomy dose metrics).
Results:
We found the higher sensitivity (0.55) for global normalization with 3%/3mm and TH= 30% and the higher specificity (0.67) with 3%/3mm for global normalization, both for TH 10% and 30%. Instead we obtained the poorer sensitivity (0) with 2%/2mm, local normalization, and TH=10% because the threshold of 95% is too high for 2%/2mm and local normalization. We observed the poorer specificity (0.39) for 3%/3mm, local normalization, both for TH=10% and 30%. For global normalization, 3%/3mm sensitivity and specificity were always higher than those of 2%/2mm criterion.
Conclusion:
The low sensitivity and specificity values of GI method, for all the applied criteria, show that the gamma index metric have disputable predictive power for perpatient Tomotherapy QA. Purpose or Objective: The gamma index (γ) is a common method for comparing measured and predicted dose distributions. The percentage of points passing with γ<1 (Γ) is the most frequently reported analysis metric. However, the use of Γ has been reported to have weak correlation against clinically relevant metrics and the result also varies depending on the Quality Assurance (QA) system configuration and software used. Other metrics could be extracted from the γ map but have not been rigorously evaluated in the literature to address appropriate acceptance values. This study has developed a methodology to evaluate the suitability of the mean, median, maximum, or nearmaximum γ metrics (γmean, γmedian, γmax, γ1%) and their acceptance criteria.
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Material and Methods:
Investigations were performed using simulated data with deliberate changes created in a virtual phantom test. The changes included: dose deviations of -5% to 5% in 1% steps; and MLC offsets of 1-5mm in 1mm steps. An in-house Matlab-based software was used to perform γ analysis to extract different metrics. The primary PTV mean (PTVmean) and organ at risk maximum (OARmax) dose deviations were extracted from the changed plans. The γ metrics were correlated against PTVmean and OARmax for global γ passing criteria of 3%/2mm (20% threshold relative to a point in high dose low gradient). Acceptance criteria needed to predict a dose deviation >±3%, for 3%/2mm, were assessed using Receiver Operator Characteristic (ROC) analysis and assuming 100% sensitivity. The area under the ROC curve (AUC) was assessed for each γ metric to assess statistical reliability. Since the γ calculation can give varying results between different QA systems, the robustness of the proposed methodology was tested by varying γ passing criteria as well calculating in 2D planes and 3D volumes.
Results:
The γmean, γmedian and γ1% metrics had the strongest Pearson correlation coefficient (ρ) against the PTVmean (ρ>0.95, p<0.01); (Fig. 1) . The Γ had a weaker correlation of ρ=-0.76. These metrics had ROC AUC>0.9 (p<0.01) showing statistically strong accuracy for predicting a PTVmean deviation >±3% for 3%/2mm. Optimal acceptance criteria for achieving 100% sensitivity are shown in Table 1 . The γmax had the best correlation against OARmax (ρ> 0.8, p<0.01) and the AUC was >0.9 and showed that points with γ>1.1 may be associated with a >3% increase in the OARmax. Correlations between different γ passing criteria were statistically strong at >0.95 (p<0.01) as were correlations between 2D & 3D γ calculations, indicating the robustness of the methodology to the variability in γ calculation that could be caused by QA system configuration and software implementation.
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Purpose or Objective: Aim of this study is the evaluation of build-up and superficial doses for a Head&Neck treatment, delivered by Helical TomoTherapy (HT). Measurements were carried out by two different dosimeters (radiochromic films and a synthetic single crystal diamond detector) and compared with TPS data. Build-up dose profiles and superficial dose points were estimated. The reliability of the TPS in these critical regions was assessed, giving an insight into a subject on which quite contradictory results are reported in the literature.
Material and Methods:
A home modified Anderson Rando phantom was employed to house the detectors. As shown in figure (a) , two slices of the phantom neck were removed and replaced with a PMMA artificial neck, with a hole inside to mimic the trachea. This allowed to measure dose profiles and superficial dose points with geometrical and scattering conditions similar to the ones taking place when a real patient is treated. Gafchromic EBT3 films (Ashland Inc., Wayne, NJ) were sandwiched inside the neck in oder to measure dose profiles and attached to the neck surface for superficial dose point assessment. PTW-Frieburg microDiamond (mD) was positioned inside drilled holes at different known distances respect to the phantom surface.
Results:
In figure (b) one of the measured dose profiles by EBT3 and mD is reported, along the Antero-Posterior direction, in the range 0-30 mm (distance from the phantom surface). TPS data are also shown, as black dots, with an associated error of ± 0.9 mm, half of the lateral dimension of the calculation pixel (fine grid). The prescribed dose is reached within approximately 4 mm from the phantom surface and it does not show any significant variation going further inside the neck, in particular at the PMMA/air interface, in correspondence of the trachea starting point. A 1D threshold criterion of 3%/mm was adopted in order to discriminate between high and low gradient zones. Dose differences (DD) measured by mD are within 2.5% respect to TPS, in the low gradient region, while a maximum distanceto-agreement (DTA) of 0.9 mm is found for the same device, in the high gradient region. EBT3 profile shows a more noisy behavior, with a maximum DD of 3.8% in the low gradient portion of the profile, while DTA is less than 1 mm in the high gradient zone. The superficial dose measurement by EBT3 film is characterized by a DTA of 0.5 mm and a DD of 5.2%.
Conclusion:
Build-up dose profiles measured by the two dosimeters show the same behavior and are in agreement with TPS data; deviations are well within the reference tolerance level. The investigation carried out in this work offers the possibility of studying the TPS behavior not only in terms of dose difference, as carried out for in vivo measurements, but also taking into account a "spatial displacement", to be compared with patient (and/or dosimeter) positioning uncertainties.
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Verification of small-field VMAT plans using a 2D detector array in a rotational phantom A. Swinnen 1 MAASTRO clinic, Radiotherapy, Maastricht, The Netherlands 1 , M. Ollers 1 , E. Roijen 1 , S. Nijsten 1 , F. Verhaegen 1 Purpose or Objective: To evaluate experimentally the accuracy of the dose calculation algorithm AcurosXB in smallfield highly modulated Volumetric Modulated Arc Therapy (VMAT).
Material and Methods:
The Octavius 1000SRS detector array inserted in the rotational Octavius4D phantom (PTW) was used, consisting of 977 liquid-filled ion chambers covering an area of 11×11cm2. The detector size (2.3×2.3×0.5mm3) and the center-to-center distance of the detectors (2.5mm in the inner 5.5×5.5cm2 area) are important parameters for correct spatial measurement of complex dose distributions with steep dose gradients. Clinical treatment plans (n = 28), characterized by small treatment volumes, 6 and 10MV photon beams, and fraction doses between 2.75-30 Gy, were projected on the phantom CT data set and recalculated in the Eclipse TPS v11 (Varian Medical Systems) using AcurosXB with a calculation grid size of 2.5mm and 1mm (field sizes <3x3cm2). All measurements were done on a Varian TrueBeamSTx linac. The irradiation technique used was
